Sharon Navon
CEO
Claimed by owner I-Derm Pharma
Former names:
Nonsteroidal Treatment for Inflammatory Skin Diseases
I-Derm Pharma
About
I-Derm develops a nonsteroidal topical treatment for inflammatory skin diseases based on a novel mechanism of action. This mechanism directly targets cutaneous elements rather than the immune system and is therefore uniquely functional only on the skin. This novel treatment is targeted as a nonsteroidal topical treatment for psoriasis.
The molecule, CPT-11, up-regulates SAMD9, which in turn down-regulates EGR1, a critical regulator of inflammatory responses of the skin, in a dose-dependent manner.
The molecule, CPT-11, up-regulates SAMD9, which in turn down-regulates EGR1, a critical regulator of inflammatory responses of the skin, in a dose-dependent manner.
Primary Sector
Life Sciences & HealthTech
Products
-
Geographic markets
-
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
1
Investors
1
News
(0)The Team
(3)
SN
ES
Eli Sprecher
Co-founder & Scientific and Clinical Advisor
OS
Ofer Sarig
Co-כounder & Scientific Advisor
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
Pre-Seed
Undisclosed
Mar 2022
1 Investors
Undisclosed
Media gallery
(0)Locations
Israel
Wadi el-Haj St 13, Nazareth, Israel
Locations
Israel
Wadi el-Haj St 13, Nazareth, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,